Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

The embedded finance company, which posted a loss last year, hired Citigroup to explore its strategic options and named an ...

William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...

Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...

Equities research analysts at William Blair cut their Q4 2026 earnings estimates for shares of Duluth in a research report issued to clients and investors on Thursday, March 13th. William Blair ...

The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...